These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 6602754

  • 1. Heparin-stimulated modification of C1-inhibitor by subcomponent C1s of human complement.
    Weiss V, Engel J.
    Hoppe Seylers Z Physiol Chem; 1983 Mar; 364(3):295-301. PubMed ID: 6602754
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.
    Harpel PC, Cooper NR.
    J Clin Invest; 1975 Mar; 55(3):593-604. PubMed ID: 123251
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. C1 inactivator-C1s complexes in inflammatory joint disease.
    Inman RD, Harpel PC.
    Clin Exp Immunol; 1983 Sep; 53(3):521-8. PubMed ID: 6604603
    [Abstract] [Full Text] [Related]

  • 8. Structural and circular-dichroism studies on the interaction between human C1-esterase inhibitor and C1s.
    Nilsson T, Sjöholm I, Wiman B.
    Biochem J; 1983 Sep 01; 213(3):617-24. PubMed ID: 6604523
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Fluid-phase interaction of C1 inhibitor (C1 Inh) and the subcomponents C1r and C1s of the first component of complement, C1.
    Chesne S, Villiers CL, Arlaud GJ, Lacroix MB, Colomb MG.
    Biochem J; 1982 Jan 01; 201(1):61-70. PubMed ID: 6282262
    [Abstract] [Full Text] [Related]

  • 11. C1 subcomponent complexes: basic and clinical aspects.
    Laurell AB, Sjöholm AG.
    Behring Inst Mitt; 1993 Dec 01; (93):292-8. PubMed ID: 8172579
    [Abstract] [Full Text] [Related]

  • 12. Functional analysis of activated C1s, a subcomponent of the first component of human complement, by monoclonal antibodies.
    Matsumoto M, Nagaki K.
    J Immunol; 1986 Nov 01; 137(9):2907-12. PubMed ID: 2428878
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Kinetics of the reaction between human C1-esterase inhibitor and C1r or C1s.
    Nilsson T, Wiman B.
    Eur J Biochem; 1983 Jan 01; 129(3):663-7. PubMed ID: 6297891
    [No Abstract] [Full Text] [Related]

  • 17. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma.
    Wuillemin WA, te Velthuis H, Lubbers YT, de Ruig CP, Eldering E, Hack CE.
    J Immunol; 1997 Aug 15; 159(4):1953-60. PubMed ID: 9257861
    [Abstract] [Full Text] [Related]

  • 18. Effect of plicatic acid on human serum complement includes interference with C1 inhibitor function.
    Giclas PC.
    J Immunol; 1982 Jul 15; 129(1):168-72. PubMed ID: 6979566
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [New preparation method of C1 esterase for the dosage of its plasma inhibitor].
    Gozin D, Ollier-Hartmann MP, Lerable J, Hartmann L, Soulier JP.
    Biomed Pharmacother; 1983 Jul 15; 37(5):228-30. PubMed ID: 6607074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.